title: Evidence based information on drug use during pregnancy: a survey of community pharmacists in three countries.
abstract: OBJECTIVE
  To evaluate whether community pharmacists provide evidence-based information to women inquiring about specific drug use during pregnancy.
  
  
  METHODS
  A trained female student posing as a surrogate shopper requested information about the relative safety/risks of medications during pregnancy in two scenarios. Forty randomly selected pharmacies were surveyed in the Netherlands, Canada and Iceland, and pharmacists' recommendations were noted. Main outcome measures included the type of information that was provided, its presentation, and the source of information used.
  
  
  RESULTS
  A relatively small proportion of pharmacists surveyed, provided evidence-based information regarding the drugs in question. Only 14% referred to current medical literature, while 60% consulted the product monograph. Over 90% of pharmacists referred the client to a physician.
  
  
  CONCLUSIONS
  Community pharmacists do not disseminate evidence-based recommendations when counseling women on drug use in pregnancy, and need further education on resources concerning drugs in pregnancy that are currently available.
authors: Motherisk Program, Division of Clinical Pharmacology, Hospital for Sick Children, 555 University Avenue, Toronto, ON M5G 1X8, Cananda.
authors: D A
authors: DA
authors: Lyszkiewicz
authors: S
authors: S
authors: Gerichhausen
authors: I
authors: I
authors: Björnsdóttir
authors: T R
authors: TR
authors: Einarson
authors: G
authors: G
authors: Koren
authors: A
authors: A
authors: Einarson
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects; D000994:Antitrichomonal Agents / Q000009:adverse effects; D002170:Canada; D002220:Carbamazepine / Q000009:adverse effects; D004363:Drug Utilization / Q000706:statistics & numerical data*; D064420:Drug-Related Side Effects and Adverse Reactions; D019317:Evidence-Based Medicine; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects; D006801:Humans; D007055:Iceland; D008795:Metronidazole / Q000009:adverse effects; D009426:Netherlands; D010353:Patient Education as Topic; D010594:Pharmacies; D010595:Pharmacists; D011247:Pregnancy / Q000523:psychology*
chemical_list: D000927:Anticonvulsants; D018687:Antidepressive Agents, Second-Generation; D000994:Antitrichomonal Agents; D005473:Fluoxetine; D008795:Metronidazole; D002220:Carbamazepine